Description

FINOBRATE 160 MG

Indications

FINOBRATE 160 MG is primarily indicated for the management of dyslipidemia, a condition characterized by abnormal lipid levels in the blood, including elevated triglycerides and low levels of high-density lipoprotein (HDL) cholesterol. It is often prescribed to patients at risk of cardiovascular diseases, including those with a history of heart attack, stroke, or other cardiovascular conditions. Additionally, FINOBRATE may be used as an adjunct to diet and lifestyle modifications to enhance lipid profiles and reduce the risk of atherosclerosis.

Mechanism of Action

FINOBRATE contains fenofibrate as its active ingredient, which belongs to the class of fibrates. The primary mechanism of action of fenofibrate is the activation of peroxisome proliferator-activated receptor alpha (PPARα). This activation leads to increased lipolysis and elimination of triglyceride-rich particles from plasma. Fenofibrate also enhances the activity of lipoprotein lipase, an enzyme that breaks down triglycerides, thereby reducing triglyceride levels in the bloodstream. Additionally, it promotes the synthesis of HDL cholesterol, contributing to improved lipid profiles.

Pharmacological Properties

FINOBRATE is rapidly absorbed following oral administration, with peak plasma concentrations typically occurring within 2 to 4 hours. The bioavailability of fenofibrate is influenced by food intake, with higher absorption noted when taken with meals. Fenofibrate is highly protein-bound (approximately 99%), primarily to albumin. The drug undergoes extensive hepatic metabolism, primarily through the cytochrome P450 system, leading to the formation of active metabolites. The elimination half-life of fenofibrate ranges from 20 to 30 hours, allowing for once-daily dosing. The drug is excreted mainly via the kidneys, and caution is advised in patients with renal impairment.

Contraindications

FINOBRATE is contraindicated in patients with known hypersensitivity to fenofibrate or any of its components. It should not be used in individuals with severe hepatic impairment, including primary biliary cirrhosis, or in those with gallbladder disease. Additionally, the use of FINOBRATE is contraindicated in patients with severe renal impairment or those undergoing dialysis, as the drug may accumulate and lead to increased risk of adverse effects. Pregnant and breastfeeding women should avoid using FINOBRATE due to potential risks to the fetus or infant.

Side Effects

Common side effects associated with FINOBRATE include gastrointestinal disturbances such as abdominal pain, nausea, vomiting, and diarrhea. Other reported side effects may include headache, dizziness, and fatigue. Rare but serious adverse effects include hepatotoxicity, pancreatitis, and myopathy, which can progress to rhabdomyolysis, particularly when used in conjunction with statins. Routine monitoring of liver function tests and renal function is recommended during treatment to detect any abnormalities early.

Dosage and Administration

The recommended dosage of FINOBRATE is typically 160 mg once daily, taken with food to enhance absorption. It is essential to adhere to the prescribed dosage and not exceed the recommended amount, as higher doses do not necessarily lead to improved therapeutic outcomes and may increase the risk of side effects. Patients should be advised to maintain a low-fat diet and engage in regular physical activity as part of their overall management plan. Regular follow-up appointments are necessary to monitor lipid levels and assess the efficacy of treatment.

Interactions

FINOBRATE may interact with several medications, potentially altering their effects or increasing the risk of adverse reactions. Notably, concomitant use with statins may increase the risk of myopathy and rhabdomyolysis; therefore, careful monitoring is required if these medications are prescribed together. Other potential drug interactions include anticoagulants, which may have altered effects when used with FINOBRATE. It is crucial for patients to inform their healthcare provider of all medications, supplements, and herbal products they are taking to avoid possible interactions.

Precautions

Before initiating treatment with FINOBRATE, healthcare providers should assess the patient’s medical history, particularly regarding liver and kidney function. Regular monitoring of liver enzymes and renal function is recommended, especially in patients with pre-existing conditions. Caution is advised in elderly patients and those with a history of gallstones, as fenofibrate may exacerbate these conditions. Patients should be informed about the signs and symptoms of potential side effects, particularly muscle pain or weakness, and advised to seek medical attention if these occur.

Clinical Studies

Clinical studies have demonstrated the efficacy of FINOBRATE in improving lipid profiles and reducing cardiovascular risk. A pivotal study published in the Journal of Clinical Lipidology indicated that fenofibrate significantly reduced triglyceride levels and increased HDL cholesterol in patients with mixed dyslipidemia. Another study showed that fenofibrate, when used in conjunction with statins, provided additional benefits in lipid management and cardiovascular outcomes. However, the combination therapy must be approached with caution due to the increased risk of muscle-related side effects.

Conclusion

FINOBRATE 160 MG is a valuable therapeutic option for managing dyslipidemia and reducing cardiovascular risk. Its mechanism of action through PPARα activation leads to significant improvements in lipid profiles. While generally well-tolerated, it is essential for healthcare providers to monitor patients for potential side effects and drug interactions. Adherence to prescribed dosages, along with lifestyle modifications, will enhance the effectiveness of treatment. As with any medication, informed patient participation and regular follow-up are crucial for achieving optimal health outcomes.